RecruitingNCT06100965
Reduced-dose Alemtuzumab for Kidney Transplant Rejection
The Effects of Reduced Dose Alemtuzumab for Severe Kidney Transplant Rejection
Sponsor
Erasmus Medical Center
Enrollment
25 participants
Start Date
Dec 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
Prospective, follow-up study of kidney transplant recipients treated with alemtuzumab anti-rejection therapy for severe or glucocorticoid-resistant kidney transplant rejection.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- years or older
- Treatment for severe or glucocorticoid-resistant kidney transplant rejection with alemtuzumab.
Exclusion Criteria3
- Treatment with a different lymphocyte depleting agent (e.g. rATG) prior to treatment with alemtuzumab for the same rejection episode.
- Recipients who have T cell counts below 200 × 106/L before the start of therapy (for instance, because of lymphocyte depleting induction therapies).
- Inability to provide written informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06100965
Related Trials
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
NCT0741247010 locations
Trifecta-Kidney cfDNA-MMDx Study
NCT0423970331 locations
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA
NCT074158761 location
Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab
NCT070065321 location
Platelet Aggregation in the Diagnosis of Acute Graft Rejection
NCT072755411 location